Karyopharm Therapeutics Stock Price Prediction

KPTI Stock  USD 6.42  0.28  4.56%   
As of 22nd of March 2025, the RSI of Karyopharm Therapeutics' share price is approaching 37. This indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Karyopharm Therapeutics, making its price go up or down.

Momentum 37

 Sell Extended

 
Oversold
 
Overbought
The successful prediction of Karyopharm Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Karyopharm Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Karyopharm Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.26)
EPS Estimate Current Year
(12.85)
EPS Estimate Next Year
(8.21)
Wall Street Target Price
48.9286
EPS Estimate Current Quarter
(0.27)
Using Karyopharm Therapeutics hype-based prediction, you can estimate the value of Karyopharm Therapeutics from the perspective of Karyopharm Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Karyopharm Therapeutics using Karyopharm Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Karyopharm using crowd psychology based on the activity and movement of Karyopharm Therapeutics' stock price.

Karyopharm Therapeutics Implied Volatility

    
  0.97  
Karyopharm Therapeutics' implied volatility exposes the market's sentiment of Karyopharm Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Karyopharm Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Karyopharm Therapeutics stock will not fluctuate a lot when Karyopharm Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Karyopharm Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Karyopharm because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Karyopharm Therapeutics after-hype prediction price

    
  USD 6.19  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.

Prediction based on Rule 16 of the current Karyopharm contract

Based on the Rule 16, the options market is currently suggesting that Karyopharm Therapeutics will have an average daily up or down price movement of about 0.0606% per day over the life of the 2025-05-16 option contract. With Karyopharm Therapeutics trading at USD 6.42, that is roughly USD 0.003892 . If you think that the market is fully incorporating Karyopharm Therapeutics' daily price movement you should consider acquiring Karyopharm Therapeutics options at the current volatility level of 0.97%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Check out Karyopharm Therapeutics Basic Forecasting Models to cross-verify your projections.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Karyopharm Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.275.3311.85
Details
Naive
Forecast
LowNextHigh
0.336.8513.37
Details
7 Analysts
Consensus
LowTargetHigh
4.104.505.00
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-4.39-4-3.67
Details

Karyopharm Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Karyopharm Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Karyopharm Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Karyopharm Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Karyopharm Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Karyopharm Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Karyopharm Therapeutics' historical news coverage. Karyopharm Therapeutics' after-hype downside and upside margins for the prediction period are 0.31 and 12.71, respectively. We have considered Karyopharm Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
6.42
6.19
After-hype Price
12.71
Upside
Karyopharm Therapeutics is risky at this time. Analysis and calculation of next after-hype price of Karyopharm Therapeutics is based on 3 months time horizon.

Karyopharm Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Karyopharm Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Karyopharm Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.40 
6.52
  0.23 
  0.03 
6 Events / Month
14 Events / Month
In about 6 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
6.42
6.19
3.58 
1,124  
Notes

Karyopharm Therapeutics Hype Timeline

Karyopharm Therapeutics is now traded for 6.42. The entity has historical hype elasticity of -0.23, and average elasticity to hype of competition of -0.03. Karyopharm is anticipated to decline in value after the next headline, with the price expected to drop to 6.19. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.58%, whereas the daily expected return is now at -0.4%. The volatility of related hype on Karyopharm Therapeutics is about 9372.5%, with the expected price after the next announcement by competition of 6.39. About 48.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 13.95. Karyopharm Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 26th of February 2025. Given the investment horizon of 90 days the next anticipated press release will be in about 6 days.
Check out Karyopharm Therapeutics Basic Forecasting Models to cross-verify your projections.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Karyopharm Therapeutics Related Hype Analysis

Having access to credible news sources related to Karyopharm Therapeutics' direct competition is more important than ever and may enhance your ability to predict Karyopharm Therapeutics' future price movements. Getting to know how Karyopharm Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Karyopharm Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
XFORX4 Pharmaceuticals(0.05)9 per month 0.00 (0.05) 11.67 (13.51) 68.45 
HOOKHookipa Pharma 0.01 9 per month 0.00 (0.13) 7.00 (7.50) 32.80 
MREOMereo BioPharma Group 0.08 8 per month 0.00 (0.12) 6.16 (6.13) 20.77 
GRTXGalera Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
ABOSAcumen Pharmaceuticals(0.03)7 per month 0.00 (0.18) 6.57 (7.09) 19.77 
CTMXCytomX Therapeutics(0.04)10 per month 0.00 (0.13) 7.32 (7.45) 17.13 
NUVBNuvation Bio(0.01)8 per month 0.00 (0.06) 6.88 (7.38) 28.03 
NLTXNeoleukin Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
ASMBAssembly Biosciences(0.09)6 per month 0.00 (0.1) 6.63 (5.05) 24.82 
LYRALyra Therapeutics 0.00 5 per month 0.00 (0.02) 5.88 (5.88) 25.31 
REPLReplimune Group(0.18)9 per month 0.00  0.01  5.86 (4.75) 22.75 
NVCTNuvectis Pharma(0.33)9 per month 3.65  0.24  9.96 (5.84) 26.68 
KRONKronos Bio 0.03 7 per month 0.00 (0.05) 3.19 (3.16) 12.10 
GOSSGossamer Bio(0.13)7 per month 4.50  0.20  10.38 (7.62) 36.67 
AGIOAgios Pharm(0.67)9 per month 0.00 (0.04) 4.19 (4.71) 17.77 
BLUEBluebird bio 0.32 9 per month 0.00 (0.07) 12.71 (9.88) 65.23 
ICPTIntercept Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
CLVSQClovis Oncology 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
PMVPPmv Pharmaceuticals(0.04)4 per month 0.00 (0.1) 4.41 (3.31) 16.42 
RLYBRallybio Corp(0.02)6 per month 0.00 (0.14) 6.32 (6.00) 17.68 
GBIOGeneration Bio Co 0.01 7 per month 0.00 (0.22) 7.41 (7.89) 22.69 
MRSNMersana Therapeutics(0.05)9 per month 0.00 (0.23) 8.47 (12.35) 50.50 
GLUEMonte Rosa Therapeutics(0.41)8 per month 0.00  0  7.34 (7.40) 19.92 

Karyopharm Therapeutics Additional Predictive Modules

Most predictive techniques to examine Karyopharm price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Karyopharm using various technical indicators. When you analyze Karyopharm charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Karyopharm Therapeutics Predictive Indicators

The successful prediction of Karyopharm Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Karyopharm Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Karyopharm Therapeutics based on analysis of Karyopharm Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Karyopharm Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Karyopharm Therapeutics's related companies.
 2022 2023 2024 2025 (projected)
Payables Turnover1.881.581.181.12
Days Of Inventory On Hand295.75224.75287.95221.1

Story Coverage note for Karyopharm Therapeutics

The number of cover stories for Karyopharm Therapeutics depends on current market conditions and Karyopharm Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Karyopharm Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Karyopharm Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Karyopharm Therapeutics Short Properties

Karyopharm Therapeutics' future price predictability will typically decrease when Karyopharm Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Karyopharm Therapeutics often depends not only on the future outlook of the potential Karyopharm Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Karyopharm Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding126.8 M
Cash And Short Term Investments108.7 M

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years